NVDA−4.40%AAPL+1.23%GOOGL−3.15%MSFT−2.23%AMZN−4.57%TSM−4.52%SPCX−9.14%META−6.98%
StockVS

NYSE · Drug Manufacturers - Specialty & Generic · USD

Trulieve Cannabis Corp. (TRLV) Stock Analysis

Trulieve Cannabis Corp. (TRLV) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.

Last Updated: October 22, 2026

TRLV

$10.92

−$0.08 (−0.73%)

Oct 22, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TRLV with… →

TRLV Key Statistics

As of Oct 22, 2026
Trading
Open
$11.01
Previous Close
$11.00
Day's Range
10.86–11.65
52-Week Range
4.62–13.28
Volume
1.22M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.81
Valuation
Market Cap
$2.10B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
19.62
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.85
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.43
Financials (FY)
Revenue (FY)
$1.18B−0.45%
Net Income (FY)
−$116.38M
Profit marginThe share of revenue left as profit after all costs and taxes.
−41.55%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
170.16M
1-Year Return
+48.57%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
1.67M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 22, 2026, TRLV closed at $10.92, +48.57% over 1 year.

Trulieve Cannabis Corp. (TRLV) has a market capitalization of $2.10B.

In fiscal 2025, TRLV reported revenue of $1.18B.

TRLV Stock Return by Calendar Year

Trulieve Cannabis Corp. (TRLV) return since Sep 2018: what $10,000 became

1 year
$10,000 $14,857
+48.57%
5 years
$10,000 $3,949
−60.51%
Since Sep 2018
$10,000 $10,393
+3.93%

If you had invested $10,000 in Trulieve Cannabis Corp. (TRLV) at the close on September 27, 2018, the earliest close on record here, it would have been worth $10,393 at the close on October 22, 2026: +3.93% in total, +0.48% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+25.66%
2025+67.63%
2024−0.50%
2023−31.18%
2022−70.90%
2021−17.74%
2020+167.08%
2019+46.52%
2018 (partial year)−23.10%

As of October 22, 2026.

TRLV Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.18B−$116.38M−9.9%
2024$1.19B−$155.11M−13.1%
2023$1.13B−$526.80M−46.7%
2022$1.22B−$246.06M−20.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.18B$711.17M$148.32M−$116.38M−9.9%
2024$1.19B$715.75M$92.49M−$155.11M−13.1%
2023$1.13B$588.63M$92.64M−$526.80M−46.7%
2022$1.22B$689.13M$125.71M−$246.06M−20.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TRLV Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricTRLVDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio1.852.1113% below
Profit margin−41.55%−8.14%33.4 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 22, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Trulieve Cannabis Corp. (TRLV) at $2.10B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 5,000 employees.

The most recent close on file for TRLV is $10.92, dated October 22, 2026. That is −$0.08 (−0.73%) against the previous close. Over the past 52 weeks the price has ranged from $4.62 to $13.28. The latest close sits 136.57% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.18B. Against the prior fiscal year total of $1.19B, that is a change of −0.45%. The same year closed with a net loss of $116.38M. Profit margin runs at −41.55%. That is 33.4 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are −2.43.

Across the 4 fiscal years on file, revenue moves from $1.22B in 2022 to $1.18B in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 19.62. The price-to-sales ratio is 1.85. On price-to-sales that is 12.65% below the Drug Manufacturers - Specialty & Generic median of 2.11. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.81. Daily returns over the trailing 8 years annualize to a volatility of 80.68%. Over the trailing twelve months the total return is +48.57%. Measured over 5 years, that is −16.96% a year compounded.

Growth & Income

No dividend is on file for TRLV.

The strongest complete calendar year on file is 2020 at +167.08%; the weakest is 2022 at −70.90%. Of the 7 complete calendar years on file, 3 finished higher. 2026 is still running; the total return is +25.66% year to date.

Peer Comparison

Trulieve Cannabis Corp. (TRLV) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Trulieve Cannabis Corp. TRLV $2.10B —
Takeda Pharmaceutical Company Limited TAK $65.04B —
Teva Pharmaceutical Industries Limited TEVA $46.90B 67.0
Haleon plc HLN $45.60B 21.2

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.6x. Trulieve Cannabis Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 22, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$65.04B

 TEVA

Teva Pharmaceutical Industries Limited

$46.90B

 HLN

Haleon plc

$45.60B

 ZTS

Zoetis Inc.

$33.88B

 UTHR

United Therapeutics Corporation

$25.08B

 VTRS

Viatris Inc.

$21.23B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.17T

 JNJ

Johnson & Johnson

$644.91B

 ABBV

AbbVie Inc.

$503.96B

 UNH

UnitedHealth Group Incorporated

$381.46B

 MRK

Merck & Co., Inc.

$363.27B
View all Healthcare stocks →

About Trulieve Cannabis Corp.

Trulieve Cannabis Corp. operates as a cannabis retailer in the United States. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery. It sells flowers, edibles, vapes, oral, topical, concentrates, and accessories under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, and Roll One brands. The company operates dispensaries in Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. It operates cultivation and processing facilities in Arizona, Colorado, Florida, Georgia, Maryland, Pennsylvania, and West Virginia. The company also offers medical cannabis dispensary in North Miami Beach, Florida. Trulieve Cannabis Corp. was formerly known as Schyan Exploration Inc./Exploration Schyan Inc. and changed its name to Trulieve Cannabis Corp. in September 2018. Trulieve Cannabis Corp. was incorporated in 1940 and is headquartered in Tallahassee, Florida.

Visit website →